ABSTRACT
sFLT01 is a novel fusion protein that consists of the VEGF/PlGF binding domain of human VEGFR1/Flt-1 (hVEGFR1) fused to the Fc portion of human IgG 1 through a polyglycine linker. sFLT01 binds to both human VEGF (hVEGF) and human PlGF (hPlGF) as well as to mouse VEGF (mVEGF) and mouse PlGF (mPlGF). In vitro, sFLT01 inhibited the proliferation of HUVEC and pericytes stimulated by either hVEGF or hPlGF. In vivo, sFLT01 had robust and significant anti-tumor activity in numerous preclinical subcutaneous tumor models including H460 non-small cell lung carcinoma (NSCLC), HT29 colon carcinoma, Karpas 299 lymphoma, MOLM-13 acute myeloid leukemia (AML), 786-O and RENCA renal cell carcinoma (RCC). sFLT01 also increased median survival in the orthotopic RENCA RCC model. sFLT01 had strong anti-angiogenic activity and altered intratumoral microvessel density (MVD), blood vessel lumen size and perimeter, and vascular and vessel areas in RCC models. sFLT01 treatment resulted in fewer endothelial cells and pericytes within the tumor microenvironment. sFLT01 in combination with cyclophosphamide resulted in greater inhibition of tumor growth than either agent as a monotherapy in the A673 Ewing's sarcoma model. Gene expression profiling indicated that the molecular changes in the A673 sarcoma tumors are similar to changes observed under hypoxic conditions. sFLT01 is an innovative fusion protein that possessed robust anti-tumor and antiangiogenic activity in preclinical cancer models. sFLT01 is a dual targeting agent that neutralizes both VEGF and PlGF and therefore has potential as a next generation antiangiogenic therapeutic for oncology.
INTRODUCTION
The recognition that tumors require an active network of blood vessels for growth and metastasis generated the field of angiogenesis research. Vascular endothelial growth factor (VEGF) was identified as a major contributor to the angiogenesis process under both physiological and pathological conditions that include cancer (1) . Multiple isoforms of VEGF and multiple splice variants of VEGF-A have been implicated in the progression of malignant disease. The various species of VEGF bind to any of several VEGF receptors and the neuropilin co-receptors on the cell surface. The development of anti-angiogenic therapies targeting VEGF pathways followed their elucidation.
Bevacizumab, a humanized monoclonal antibody that neutralizes human VEGF-A, was the first approved anti-angiogenic drug for use with chemotherapy in metastatic colorectal cancer patients (2) . Subsequently, sunitinib and sorafenib, small molecule multi-targeted tyrosine kinase inhibitors, were approved for advanced renal cell carcinoma (RCC), a highly vascularized disease characterized by VEGF overexpression (3) . However, although VEGF is a well-validated target, the overall survival benefit with the first generation anti-angiogenic therapies that inhibit VEGF pathways has been modest and there remains a need to improve upon the standard of care.
Placental growth factor (PlGF) is a member of the VEGF family and can form heterodimers with VEGF (4, 5). Several splice variants of PlGF exist that bind to VEGFR1/Flt-1 and/or neuropilin-1 (6, 7). PlGF angiogenic activity was demonstrated in transgenic mice where the overexpression of PlGF resulted in a substantial increase in vasculature including the number of vessels, branching points, size of the vessels, and increased vascular permeability (8) . PlGF is overexpressed in multiple human 4 malignancies including renal, breast, gastric and lung carcinomas, and brain tumors (9) (10) (11) (12) (13) (14) (15) . PlGF has potential as a prognostic biomarker in breast, colon, and lung cancers because higher PlGF circulating levels are associated with more aggressive disease (10, (15) (16) (17) . The therapeutic potential of PlGF neutralization was demonstrated with an antiPlGF antibody that inhibited the growth of tumors in preclinical models of melanoma, pancreatic cancer, and colon carcinoma (18) .
Serum PlGF levels increase following cancer therapy and PlGF is one of several factors implicated in therapeutic resistance, post therapy angiogenesis, and tumor regrowth (19) . PlGF was associated with early recurrence of hepatocellular carcinoma following radical resection and was upregulated in preclinical lung and colon adenocarcinoma tumors following radioimmunotherapy (20, 21) . In colorectal cancer patients with metastatic disease, serum PlGF increased following the administration of bevacizumab in combination with chemotherapy and/or radiation (22, 23) . VEGF-A and PlGF levels increased following sunitinib treatment in patients with bevacizumabrefractory metastatic renal cell carcinoma (RCC) and in men with advanced prostate cancer who were treated with sunitinib (24, 25) . Thus, PlGF may have a role in resistance to certain antiangiogenic therapies and PlGF neutralization may overcome resistance to VEGF receptor inhibitors (26) .
We have investigated the potential value of targeting both VEGF and PlGF for oncology using sFLT01, a novel fusion protein that consists of the VEGF/PlGF binding domain of human VEGFR1/Flt-1 (hVEGFR1) fused to the Fc portion of human IgG 1 through a polyglycine linker (9Gly) (27) . sFLT01 has a molecular weight of approximately 80kDa and does not contain the extracellular domain 3 of VEGFR2 as antibody that cross-reacts with human and mouse VEGFR2 (1/1,000) (Upstate (Millipore), Billerica, MA) was applied for 60 min. After 2 washes 5 μg/ml goat antihuman IgG 1 CY2-labeled antibody (Jackson Immunochemicals) and 2.5 μg/ml goat antirabbit-CY3 antibody (Jackson Immunochemicals) were applied to the tissue sections for 30 min to allow simultaneous detection of VEGFR2 and sFLT01.
Statistical analysis.
In vitro data are expressed as mean +/-SD. Comparisons between treatment and control groups were made using student's t-test. Tumor volumes are expressed as mean+/-SEM and were analyzed by ANOVA test. Kaplan-Meier survival curves were analyzed by the log-rank test. Graphpad Prism5.0 (Graphpad Software, Inc., La Jolla, CA) was used for analysis. P<0.05 was considered statistically significant. Figure 1B ). These data demonstrate the cross-species reactive property of sFLT01.
The in vitro activity of sFLT01 was evaluated in cell-based proliferation assays using HUVEC or human pericytes. Both rhVEGF-A and rhPlGF stimulated HUVEC to proliferate which was inhibited by sFLT01 in a concentration dependent manner and generated EC 50 values of approximately 100 ng/ml and 120 ng/ml respectively ( Figure   1C ). Similarly, rhVEGF-A and rhPlGF enhanced the proliferation of pericytes. sFLT01 By comparison, the blood vessels in the tumors from mice treated with four doses of sFLT01 and collected one day later were fragmented, lacked lumen formation, and were notably smaller ( Figure 3C ). Morphometric analysis revealed that although the microvessel density (MVD) was not reduced by sFLT01 treatment due to an increase in smaller, fragmented vessels, the vessel and vascular area, lumen size, and the vessel perimeter were reduced although the difference was not statistically significant (P>0.05) ( Figure 3D ).
In addition to hVEGF-A and hPlGF, sFLT01 binds to mVEGF-A and to mPlGF
( Figure 1A, B) 
Preclinical studies have value in gauging the efficacy of anti-angiogenic agents but may not necessarily predict toxicities that could be experienced in the clinic in combination therapies. For example, RCC patients experienced unacceptable side effects from a combination of bevacizumab and sunitinib that resulted in the discontinuation of a clinical trial (33) . Differences between the human and mouse species exist with regards to pharmacokinetic and pharmacodynamic parameters, immune-mediated responses, and the tumor microenvironment. These dissimilarities can hinder the ability to fully translate the results generated in preclinical models to the clinical setting.
While the therapeutic benefit of interfering with the VEGF pathways has been robust in preclinical tumor models and validated in the clinic, the effect is modest and additional research is emerging which suggests that targeting PlGF may have value. PlGF overexpression in numerous human specimens of a variety of carcinomas vs. normal counterpart tissues has been well documented (9) (10) (11) (12) (13) (14) (15) neutralizing PlGF in addition to VEGF at the onset may be more effective than a single target approach. However, this strategy is not without controversy as conflicting reports exist based on results generated in preclinical studies (35, 36) . The value of a combinatorial approach against VEGF and PlGF will ultimately need to be determined in a clinical setting in a heterogeneous patient population that receives not only antiangiogenic therapy but other modalities of treatment such as radiation and chemotherapy. 
Alternatively, a drug such as sFLT01 may hold value as a second-line antiangiogenic agent in consideration of clinical data which suggest that PlGF may play a role in resistance to anti-angiogenic therapies and tumor escape. Serum PlGF levels increased in colorectal cancer patients following bevacizumab therapy (22, 23) . Similar observations have been made in patients with metastatic RCC who no longer responded to bevacizumab or in patients with prostate cancer who were treated with sunitinib (24, 25) . The administration of sFLT01 to patients with elevated serum PlGF levels could offer a novel approach to neutralize PlGF that may be contributing to drug resistance and tumor escape. Since other factors may contribute to anti-angiogenic resistance (37, 38), patients would be prescreened prior to sFLT01 therapy to identify the subpopulation who would most likely respond. As a soluble decoy receptor, sFLT01 would neutralize PlGF independent of its source, i.e., malignant cells and stroma or host tissues (19) .
Some anti-angiogenic drugs such as bevacizumab provide little benefit as a monotherapy and are delivered in combination with other treatments as standard of care (11, 39) . While sFLT01 alone was efficacious in the A673 sarcoma model, sFLT01 generated a greater benefit in combination therapy with cyclophosphamide compared to cyclophosphamide alone. This result suggests that an improved outcome could be achieved in the clinic with the incorporation of sFLT01 into a chemotherapy regimen. cytotoxic agents (41) . Thus, the anti-angiogenic properties of sFLT01 could be another useful combination strategy for oncology treatments.
With pathological overexpression of VEGF and PlGF implicated in other diseases including age-related macular degeneration, diabetic retinopathy, and inflammatory disorders (32, 34, 42-45) , the potential value of sFLT01 as an anti-angiogenic drug extends beyond cancer therapy. Indeed, bevacizumab, which is approved for the treatment of certain cancers, is being investigated to treat neovascular macular degeneration (46) . sFLT01 may offer a greater benefit in patients where PlGF in addition to VEGF is involved in the pathogenesis of this disease as well as other vascular disorders, thereby expanding its utility in the clinic.
Several drugs have been developed that either directly target PlGF or bind to the receptor, VEGFR1, as agonists. Multi-targeted tyrosine kinase inhibitors such as sorafenib and sunitinib are FDA-approved but do not selectively interfere solely with the PlGF pathways as they also have activity against the PDGF, VEGFR2, Flt3, and c-kit pathways (11) . TB-403 is a monoclonal antibody against PlGF and is currently in Phase I clinical trials (26, 47) . Aflibercept that most closely resembles sFLT01 in structure is in Phase III trials for several cancer indications (48) . Although it is not expected that an antiangiogenic drug will be fully efficacious as a stand alone therapy, sFLT01 is a novel, next generation antiangiogenic agent with ability to bind to both VEGF and PlGF with a 
